Atara Bio to Present at the JMP Securities Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., June 15, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 9:00 a.m. ET.  The conference will be held at The St. Regis New York Hotel in New York, NY.

A live webcast of the presentation will be available by visiting the Investors section of the Atara Bio website at www.atarabio.com. An archived replay of the webcast will be available on the Company's website for 14 days following the presentation.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, with an initial focus on immunotherapy and oncology. Atara Bio's programs include T cell product candidates and molecularly targeted product candidates. The T cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.

INVESTOR & MEDIA CONTACT:

Investors:   
Steve Klass  
212-213-0006 x331 
[email protected]  

Media:
Justin Jackson
212-213-0006 x327
[email protected]

You May Also Be Interested In

• Interstate Carbonic Launches 8-State Dry Ice Blasting from McKinney
• 5 Best Crypto Presales as Bitcoin Falls Below $78K and $480M in Leverage Gets Wiped Out
• Cardano Price Prediction: Can ADA Reach $1 While AlphaPepe Chases 100x Potential From $0.02845?